As filed with the Securities and Exchange Commission on December 22, 2025 Registration No. 333-290996 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Graphjet Technology (Exact name of registrant as specified in its charter) Cayman Islands 3620 N/A (State or other jurisdiction of incorporation or organization) (Primary standard industrial classification code number) (I.R.S. Employer Identification Num ...

Key Takeaways FOLD touched a 52-week high as shares rally 87.6% in six months, beating the industry, sector and S&P 500.Galafold is the key revenue driver, generating $371.5M in the first nine months of 2025, up 12% Y/Y.Pombiliti Opfolda sales reached $77.5M in the first nine months of 2025, reflecting 61.5% y/y growth.Shares of Amicus Therapeutics (FOLD) touched a 52-week high of $11.14 on Dec. 15. The stock is currently trading at $10.88.Shares of Amicus have surged 87.6% in the past six months compared w ...

Spurring real market competition is the best way for politicians to improve everyday life in Latin America, says @JPSpinetto (via @opinion) https://t.co/FSIgn0113w ...

Key Takeaways Brazil's operators warn that the Subsea 7-Saipem merger could alter pricing and project dynamics.Petroleum groups argue that Saipem 7 might dominate SURF work due to control of key deepwater vessels.Cade is gathering global input as Brazil becomes the pivotal arena for the merger's approval.The proposed merger between Subsea 7 S.A. ((SUBCY) and Saipem SpA has sparked a rare unified response from Brazil’s major oil operators, who warn that the deal could reshape competition in one of the world’ ...

In LGFV space, we saw better buying across the credit curve. Chinese RMs/AMs were buying the front end, whilst HFs and retails the higher- yielding issues. Fixed Income Credit Commentary 1 Dec 2025 Glenn Ko, CFA 高志和 (852) 3657 6235 glennko@cmbi.com.hk CMBI Credit Commentary Fixed Income Daily Market Update 固定收益部市场日报 Trading desk comments 交易台市场观点 Last Friday, we saw small better buying on JP/AU financial names MIZUHO/SUMIBK/QBEAU/ANZ/WSTP and TW lifers like NSINTW. There were balanced two-way flows on Chines ...

Core Insights - The animal health industry is facing challenges that require companies to innovate and adapt strategically [1] - Zoetis Inc. (NYSE:ZTS) is under scrutiny from KeyBanc Capital Markets regarding its product lineup and market positioning [2] - KeyBanc initiated coverage on Zoetis, highlighting ongoing challenges from its osteoarthritis (OA) pain monoclonal antibody (mAb) products and increased competition [3] Company Performance - Zoetis is experiencing headwinds from its OA pain mAb products, which have faced criticism on social media for potential side effects [4] - Despite these challenges, Zoetis is recognized for its history of innovation and is considered a high-quality company with revenue growth rates above the industry average and historically high profit margins [5] - The company reported third-quarter sales of $2.4 billion, reflecting a 1% year-over-year increase, slightly below the consensus estimate of $2.41 billion [6] Market Positioning - KeyBanc has assigned a Sector Weight rating to Zoetis until there is significant improvement in its OA pain mAb products or new high-revenue product launches [6] - Zoetis shares are currently trading at approximately 17.5x forward P/E, which is a discount compared to its two-year average of around 27x [6] - Growth in parasiticides, diagnostics, and dermatology portfolios was offset by a decline in mAb products for OA pain [7]

Summary of the Conference Call Transcript Industry Overview - The report focuses on the **China Consumer Appliances** industry, highlighting a significant decline in retail sales and market consolidation among leading brands [2][3][4]. Key Points and Arguments 1. **Retail Sales Decline**: - October omnichannel white goods retail sales fell by **29-36% YoY**, compared to a decline of **20-35% in September**. This decline is attributed to a high base in 2024 and fading domestic trade-in subsidies [2][3]. - The expectation is for continued double-digit YoY retail sales declines in November and December 2025 [2]. 2. **Market Share Dynamics**: - Industry leaders **Midea**, **Haier**, and **Gree** gained market share in October from tier-2 brands like **AUX** and **Hisense**, indicating ongoing industry consolidation during a downcycle [2][3]. - Midea and Haier increased their offline air conditioner (AC) value share by **1ppt** and **3ppt** YoY, respectively [3]. 3. **Price Trends**: - Offline average selling prices (ASPs) for ACs, washing machines (WMs), refrigerators, and range hoods fell by **12%**, **10%**, **12%**, and **5%** YoY, respectively. This decline is primarily due to a high base from trade-in subsidies in 2024 and increased competition [3][4]. 4. **Roborock's Performance**: - **Roborock** gained market share in robot vacuum cleaners (RVCs) and wet-dry vacuum cleaners despite an overall market decline. Its online sales for RVCs grew by **177% YoY**, while its market share increased by **21ppt** YoY to **30%** [4]. - Concerns were raised about Roborock's profitability due to high marketing investments and self-subsidies, which may negatively impact margins in Q4 2025 [4]. 5. **Small Kitchen Appliances**: - Online sales growth for small kitchen appliances decelerated to **5-10% YoY** in October 2025, with ASPs rising by **4-15% YoY** [5]. Additional Important Insights - The report indicates that the decline in retail sales is expected to persist, with industry leaders likely to continue gaining share due to brand segmentation strategies [3]. - The overall market for RVCs saw a **35% YoY** drop in online retail sales value in October, reflecting a high base from the previous year [4]. - The report emphasizes the importance of monitoring ASP trends and market share shifts as indicators of competitive dynamics within the consumer appliances sector [3][4]. Conclusion - The China Consumer Appliances industry is experiencing significant challenges with declining sales and price pressures, but leading brands are managing to consolidate their positions. Roborock's growth in a declining market highlights the potential for strategic investments to yield long-term benefits despite short-term profitability concerns.

Core Insights - Inspire Medical Systems reported strong third quarter results, driven by robust adoption of the Inspire V system and operational discipline [1] - The company experienced significant growth in patient volume and positive clinical feedback, contributing to an expanding customer base both in the U.S. and internationally [1] - CEO Tim Herbert expressed enthusiasm regarding the performance of the Inspire V system and the positive reception of its simplified procedure and comfort settings [1] Financial Performance - Revenue for Q3 was $224.5 million, exceeding analyst estimates of $220.2 million, representing a 10.5% year-on-year growth [6] - EPS (GAAP) was $0.34, significantly beating analyst estimates of -$0.19 [6] - Adjusted EBITDA reached $44.08 million, surpassing analyst expectations of $24.72 million, with a margin of 19.6% [6] - The company reaffirmed its full-year revenue guidance at $905 million and EPS guidance at $0.95, both exceeding analyst estimates [6] Market Dynamics - Sales volumes increased by 13.6% year-on-year, although this was a decrease from the 23.8% growth in the same quarter last year [6] - Market capitalization stands at $2.38 billion [6] - CEO Tim Herbert indicated expectations for accelerated growth in 2026 following the rollout of Inspire V, with formal guidance to be provided in January [6] Strategic Initiatives - The company is focusing on transitioning high-volume centers to Inspire V by year-end, while some centers may continue using Inspire IV for specific reasons [6] - Inspire Medical Systems is implementing targeted initiatives to engage ENT surgeons and expand provider capacity, with early results anticipated to be more evident in 2026 [6] - The management team is monitoring competitive dynamics closely, noting that competition is still in early stages and has not significantly impacted growth [6]

Core Insights - Starbucks Corp. has agreed to sell a 60% stake in its China business to Boyu Capital for $4 billion to enhance its operations in the country [1][2] - The partnership aims to navigate challenges posed by local competitors and changing consumer preferences in China [2][3] Company Strategy - Starbucks has approximately 8,000 stores in China and aims to grow this number to over 20,000 in the future [5] - The company has faced increased competition from domestic brands like Luckin Coffee, which offers lower-priced alternatives [3] - Recent strategies include launching free "study rooms" and expanding the menu to include more local preferences, such as sugar-free options and teas [7] Financial Performance - In the fourth quarter, comparable store sales in China increased by 2%, marking the first positive growth in over a year [5] - The estimated total value of Starbucks' retail operations in China is projected to exceed $13 billion [5] - Starbucks shares saw a slight increase of less than 1% in after-hours trading, but the stock has fallen approximately 11% this year [6] Investment Background - Boyu Capital, established in 2011, focuses on private equity investments across various sectors, including consumer and retail [4] - The decision to partner with Boyu Capital follows a competitive bidding process where five potential suitors were considered [3]

Battle of the Betting Markets heats up in the U.S. as @polymarket gets officially U.S. approval! But is it enough to overtake @kalshi's head start? https://t.co/eMHSOdM9Eb ...